Key result
Pfizer-BioNTech mRNA vaccine linked to new-onset SLE in a 24-year-old male.
Why the study?
There are scarcely reported cases of systemic lupus erythematosus development following COVID-19 mRNA vaccination.
Case Report (n=1)
This case report highlights a rare instance of new-onset Systemic Lupus Erythematosus following COVID-19 mRNA vaccination in a previously healthy young male.
The SARS-CoV-2 viral pandemic has had an immeasurable global impact, resulting in over 5 million deaths worldwide. Numerous vaccines were developed in an attempt to quell viral dissemination and reduce symptom severity among those infected. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of antinuclear autoantibodies (ANAs) with heterogenic clinical manifestations, secondary to immune complex deposition in a multitude of organ systems. There are scarcely reported cases of SLE development following COVID-19 mRNA vaccination. We present a case of a 24-year-old male without preexisting conditions or family history of autoimmune disorders, presenting with SLE following the first dose of the SARS-CoV-2 Pfizer-BioNTech mRNA vaccine.
No takes yet. Share an insight, caveat, or question.
Raviv et al. (2022) conducted a case report in Systemic lupus erythematosus (SLE) (n=1). SARS-CoV-2 Pfizer-BioNTech mRNA vaccine was evaluated on Development of Systemic lupus erythematosus (SLE). A 24-year-old male developed systemic lupus erythematosus following his first dose of the SARS-CoV-2 Pfizer-BioNTech mRNA vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: